{
    "root": "2b5b76ed-a330-4f7b-a111-467a067ee663",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Methylphenidate Hydrochloride",
    "value": "20250130",
    "ingredients": [
        {
            "name": "METHYLPHENIDATE HYDROCHLORIDE",
            "code": "4B3SC438HI"
        },
        {
            "name": "GLYCERIN",
            "code": "PDC6A3C0OX"
        },
        {
            "name": "HYDROCHLORIC ACID",
            "code": "QTT17582CB"
        },
        {
            "name": "POLYETHYLENE GLYCOL 1450",
            "code": "OJ4Z5Z32L4"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        },
        {
            "name": "GRAPE",
            "code": "6X543N684K"
        }
    ],
    "indications": "methylphenidate hydrochloride oral solution indicated treatment : • attention deficit hyperactivity disorder ( adhd ) adults pediatric patients 6 years age older • narcolepsy",
    "contraindications": "pediatric patients 6 years older : starting dose 5 mg twice daily ( breakfast lunch ) ; increase dose 5 mg 10 mg weekly ; daily 60 mg recommended . ( 2.2 ) adults : administer divided doses 2 3 times daily , preferably 30 45 minutes meals . average 20 30 mg daily . maximum recommended daily 60 mg. ( 2 )",
    "warningsAndPrecautions": "supplied methylphenidate hydrochloride oral solution 5 mg per 5 ml colorless , grape flavored liquid . supplied bottles 500 ml , ndc 27808-058-01. methylphenidate hydrochloride oral solution 10 mg per 5 ml colorless grape flavored liquid . supplied bottles 500 ml , ndc 27808-059-01. storage handling store 20° 25°c ( 68° 77°f ) [ usp controlled room temperature ] . dispense tight container child-resistant closure .",
    "adverseReactions": "methylphenidate hydrochloride oral solution contraindicated patients : known hypersensitivity methylphenidate components methylphenidate hydrochloride oral solution . hypersensitivity angioedema anaphylactic reported patients treated methylphenidate [ ( 6 ) ] . receiving concomitant treatment monoamine oxidase inhibitors ( maois ) , within 14 days following discontinuation treatment maoi , risk hypertensive crises [ ( 7 ) ] .",
    "indications_original": "Methylphenidate hydrochloride oral solution is indicated for the treatment of:\n                  • Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years of age and older\n                  • Narcolepsy",
    "contraindications_original": "Pediatric patients 6 years and older: Starting dose is 5 mg twice daily (before breakfast and lunch); increase the dose 5 mg to 10 mg weekly; daily dosage above 60 mg is not recommended. ( 2.2 ) Adults: Administer in divided doses 2 or 3 times daily, preferably 30 to 45 minutes before meals. Average dosage is 20 to 30 mg daily. Maximum recommended daily dosage is 60 mg. ( 2 )",
    "warningsAndPrecautions_original": "How Supplied\n                  \n                  Methylphenidate hydrochloride oral solution 5 mg per 5 mL is a colorless, grape flavored liquid. It is supplied in bottles of 500 mL, NDC 27808-058-01.\n                  Methylphenidate hydrochloride oral solution 10 mg per 5 mL is a colorless grape flavored liquid. It is supplied in bottles of 500 mL, NDC 27808-059-01.\n                  \n                     Storage and Handling\n                  \n                  Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].\n                  Dispense in tight container with child-resistant closure.",
    "adverseReactions_original": "Methylphenidate hydrochloride oral solution is contraindicated in patients:\n                  \n                     with known hypersensitivity to methylphenidate or other components of methylphenidate hydrochloride oral solution. Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with methylphenidate [see Adverse Reactions (\n                        \n                           6\n                        \n                        )].\n                     receiving concomitant treatment with monoamine oxidase inhibitors (MAOIs), or within 14 days following discontinuation of treatment with an MAOI, because of the risk of hypertensive crises [see Drug Interactions (\n                        \n                           7\n                        \n                        )]."
}